

ASX RELEASE

ADMEDUS ANNOUNCES LAUNCH OF CARDIOCEL® IN MALAYSIA

- CardioCel® is launched in Malaysia and registers first sales
- Malaysian launch is part of the ongoing global rollout of CardioCel
- CardioCel now implanted in over 3000 patients

Brisbane, Australia 4th November, 2015

Admedus (ASX:AHZ) has today announced that CardioCel has now been launched in Malaysia and the Company has achieved its first sales in the country.

With a population of over 30 million people as well as servicing the regional patient needs in treating cardiovascular disease, Malaysia has a strong record in the region for cardiothoracic surgery and therefore plays an important strategic market for Admedus.

CardioCel is now on market in Europe, USA, Canada, Hong Kong, Singapore, and Malaysia and continues to be accessed in the Australian market through early access programs. Admedus is also working with its partner Genpharm in the Middle Eastern and Northern Africa (MENA) region for additional regulatory approvals as well as exploring new markets in Asia.

“This is another important step in building our global CardioCel franchise, the lead product from our regenerative tissue portfolio” said Admedus CEO Mr Lee Rodne

“We are very pleased with the rollout and growing traction of our product to date. Having launched in a number of markets including the US and EU, we are delighted now to be working with key Malaysian heart centres and heart surgeons in introducing CardioCel to the region with the prospect of improving patient lives.”

“We expect CardioCel to be available in additional Malaysian centres in the coming quarters and this will add to the growing sources of CardioCel revenue in this financial year” continued Mr Rodne.

CardioCel is a bio-scaffold used to repair and treat cardiovascular defects including reconstructing and repairing heart valves to retain their native function. Admedus is currently undertaking a post-market clinical study with leading heart centres to show improved patient outcomes in reconstructing the aortic heart valve with CardioCel vs replacement bioprosthetic valves that are on the market today. The aortic heart valve replacement market is estimated to be worth more than USD \$2 billion.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

About CardioCel®

CardioCel® is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue. CardioCel® is the Admedus Group's lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group's proprietary ADAPT™ tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation. CardioCel® is a registered trademark.